Pete Ligotti
InspireMDAbout Pete Ligotti
Pete Ligotti, age 55, serves as Executive Vice President and General Manager of U.S. at InspireMD (NSPR) since January 2, 2023. He previously held senior commercial roles at NuVasive Specialized Orthopedics (VP & GM, Jan–Dec 2022), Smith+Nephew (VP Global Commercial Strategy), Integra LifeSciences (culminating as SVP & GM – Extremity Orthopedics), and began his career as Sales Manager at Clinical Neuro Systems; he holds a BA in Biology from Syracuse University and a mini‑MBA in Financial Essentials from Rutgers University . Company performance context during his tenure includes pay-versus-performance TSR and net loss metrics and the U.S. commercial launch of CGuard Prime, which delivered Q3 2025 U.S. revenue of $497,000 and total revenue of $2.5 million (+39% YoY) as the company scaled its U.S. commercial team .
Company performance context during Ligotti’s tenure
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Value of initial $100 investment based on TSR | $17 | $55 | $52 |
| Net Loss ($USD 000s) | $(18,491) | $(19,916) | $(32,005) |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| NuVasive Specialized Orthopedics (NSO) | Vice President & General Manager | Jan 2022–Dec 2022 | Led specialized orthopedics business pre-merger with Globus Medical |
| Smith+Nephew | Vice President, Global Commercial Strategy | Not disclosed | Global commercial strategy leadership in medtech |
| Integra LifeSciences | Various roles; culminated as SVP & GM – Extremity Orthopedics | Not disclosed | Ran extremity orthopedics business with increasing responsibility |
| Clinical Neuro Systems | Sales Manager | Not disclosed | Early commercial role; company later sold to Integra LifeSciences |
External Roles
No current public company board or external directorships disclosed for Mr. Ligotti in the proxy or 8-Ks .
Fixed Compensation
- Mr. Ligotti is an executive officer but is not listed as a named executive officer (NEO) in the Summary Compensation Table; no base salary, target bonus, or actual bonus details are disclosed for him in the 2024 or 2025 proxies .
Performance Compensation
- Company’s compensation program links executive pay to increased sales, profitability, and clinical trial milestones; however, individual metric weighting, targets, and payouts for Mr. Ligotti are not disclosed .
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Increased sales | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
| Profitability | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
| Clinical trial milestones | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
Equity Ownership & Alignment
Beneficial ownership
| Holder | Shares Beneficially Owned | Ownership % | As-of Date |
|---|---|---|---|
| Peter Ligotti | 333,558 | 1.09% | April 15, 2025 |
- Shares outstanding: 30,635,346 as of April 15, 2025 .
- Breakdown of vested vs. unvested shares, options in‑the‑money value, and any pledging is not disclosed for Mr. Ligotti .
Equity awards
| Grant Date | Award Type | Shares/Units | Strike Price | Expiration | Vesting | Plan |
|---|---|---|---|---|---|---|
| Jan 2, 2024 | Stock options (inducement) | 46,150 | Not disclosed | Not disclosed | Not disclosed | Outside 2021 Equity Compensation Plan |
Policies impacting alignment
- Anti‑hedging: Directors and officers are prohibited from short sales, hedging, or monetization transactions in company stock .
- Clawback: Executive Officer Clawback Policy adopted per Nasdaq Rule 10D‑1 for recovery of erroneously awarded compensation on restatements .
Employment Terms
- Role start date: January 2, 2023; he serves at the pleasure of the board, with officers holding office until death, resignation, or removal .
- No employment agreement, severance, change‑of‑control, non‑compete, or garden leave terms are disclosed for Mr. Ligotti; such terms are disclosed for other executives but not for him .
Investment Implications
- Alignment: Beneficial ownership of 333,558 shares (1.09%) indicates meaningful skin‑in‑the‑game; anti‑hedging and clawback policies strengthen alignment and downside accountability .
- Incentive structure: An inducement stock option grant (46,150 shares) suggests equity‑heavy incentives tied to future company performance, but absent disclosed vesting and strike details limit precision on timing/selling pressure analysis .
- Execution context: U.S. commercial launch progress (Q3 2025 U.S. revenue $497k, total $2.5m, +39% YoY) aligns with his U.S. leadership remit, but company losses widened as operating expenses increased to build out the U.S. team—implying continued need for disciplined commercial scaling and cost control .
- Data gaps: Lack of disclosed salary/bonus targets, vesting schedule specifics, and any pledging or ownership guideline compliance for Mr. Ligotti constrains a thorough pay‑for‑performance and retention‑risk assessment; monitor future proxies and any Form 4 filings for award vesting and transactions .